Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AOXG NASDAQ:ATON OTCMKTS:IMUN NYSE:NKGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAOXGAoxing Pharmaceutical$0.00-19.2%$0.00$0.00▼$0.01$1.98M7.811,941 shs180 shsATONPortage Biotech$0.33+3.8%$0.34$0.28▼$13.80$7.78M0.493.17 million shs9.78 million shsIMUNImmune Therapeutics$0.09$0.09$0.07▼$1.30$7.78M0.4615,246 shs12 shsNKGNNKGen Biotech$0.06$0.08$0.00▼$0.46$7.84M0.664,056 shs1,541 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAOXGAoxing Pharmaceutical-19.23%0.00%0.00%-43.24%-44.74%ATONPortage Biotech0.00%0.00%+3.75%-26.24%+33,199,900.00%IMUNImmune Therapeutics0.00%0.00%0.00%0.00%0.00%NKGNNKGen Biotech0.00%0.00%0.00%-14.29%-80.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAOXGAoxing Pharmaceutical$0.00-19.2%$0.00$0.00▼$0.01$1.98M7.811,941 shs180 shsATONPortage Biotech$0.33+3.8%$0.34$0.28▼$13.80$7.78M0.493.17 million shs9.78 million shsIMUNImmune Therapeutics$0.09$0.09$0.07▼$1.30$7.78M0.4615,246 shs12 shsNKGNNKGen Biotech$0.06$0.08$0.00▼$0.46$7.84M0.664,056 shs1,541 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAOXGAoxing Pharmaceutical-19.23%0.00%0.00%-43.24%-44.74%ATONPortage Biotech0.00%0.00%+3.75%-26.24%+33,199,900.00%IMUNImmune Therapeutics0.00%0.00%0.00%0.00%0.00%NKGNNKGen Biotech0.00%0.00%0.00%-14.29%-80.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAOXGAoxing Pharmaceutical 0.00N/AN/AN/AATONPortage Biotech 2.00Hold$2.00502.41% UpsideIMUNImmune Therapeutics 0.00N/AN/AN/ANKGNNKGen Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AOXG, NKGN, IMUN, and ATON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/24/2026ATONPortage Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$2.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/AATONPortage BiotechN/AN/AN/AN/A($0.79) per shareN/AIMUNImmune TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ANKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AN/AATONPortage Biotech-$6.77M-$8.18N/AN/AN/AN/AN/AN/AN/AIMUNImmune Therapeutics-$3.54MN/AN/AN/AN/AN/AN/A-544.75%N/ANKGNNKGen Biotech-$82.94M-$1.51N/AN/AN/AN/AN/A-479.36%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AATONPortage BiotechN/AN/AN/AN/AN/AIMUNImmune TherapeuticsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAOXGAoxing PharmaceuticalN/AN/AN/AATONPortage BiotechN/A0.880.88IMUNImmune TherapeuticsN/AN/AN/ANKGNNKGen BiotechN/A0.020.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAOXGAoxing PharmaceuticalN/AATONPortage Biotech13.36%IMUNImmune TherapeuticsN/ANKGNNKGen Biotech76.17%Insider OwnershipCompanyInsider OwnershipAOXGAoxing Pharmaceutical17.80%ATONPortage BiotechN/AIMUNImmune Therapeutics50.59%NKGNNKGen Biotech10.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAOXGAoxing Pharmaceutical350381.21 million313.35 millionNot OptionableATONPortage Biotech623.44 millionN/AN/AIMUNImmune Therapeutics283.66 million41.34 millionNot OptionableNKGNNKGen BiotechN/A130.60 million40.29 millionNot OptionableAOXG, NKGN, IMUN, and ATON HeadlinesRecent News About These CompaniesNKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support EnrollmentMay 19 at 8:16 PM | markets.businessinsider.comNKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support EnrollmentMay 19 at 8:05 AM | globenewswire.comNKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development SummitApril 10, 2026 | finance.yahoo.comNKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development SummitApril 9, 2026 | globenewswire.comNKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™March 23, 2026 | markets.businessinsider.comNKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™March 23, 2026 | globenewswire.comNKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026March 10, 2026 | markets.businessinsider.comNKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026March 10, 2026 | globenewswire.comNKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory BoardJanuary 22, 2026 | markets.businessinsider.comNKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D.January 22, 2026 | globenewswire.comNKGen Biotech issues statement on NKGen Korea board appointmentsDecember 3, 2025 | msn.comNKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.December 3, 2025 | markets.businessinsider.comNKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert MarketOctober 9, 2025 | globenewswire.comNKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of NeurologyOctober 6, 2025 | globenewswire.comNKGen Biotech Announces Consulting Agreement with Dr. KimOctober 1, 2025 | msn.comNKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy ForumSeptember 18, 2025 | globenewswire.comNKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property AssetsSeptember 9, 2025 | globenewswire.comNKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology SummitAugust 6, 2025 | globenewswire.comNKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025July 29, 2025 | finance.yahoo.comNKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025July 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAOXG, NKGN, IMUN, and ATON Company DescriptionsAoxing Pharmaceutical OTCMKTS:AOXG$0.0042 0.00 (-19.23%) As of 05/19/2026 09:34 AM EasternAoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.Portage Biotech NASDAQ:ATON$0.33 +0.01 (+3.75%) Closing price 04/20/2026Extended Trading$0.33 0.00 (0.00%) As of 04/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.Immune Therapeutics OTCMKTS:IMUN$0.09 0.00 (0.00%) As of 10/19/2023Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.NKGen Biotech NYSE:NKGN$0.06 0.00 (0.00%) As of 05/18/2026 01:15 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
